Dr. John studies metabolism in the setting of pediatric infections, in order to identify new anti-infective drug targets, understand drug resistance, and develop new diagnostics.
Dr. Maris investigates the molecular and genetic mechanisms contributing to the development and progression of neuroblastoma, a common childhood cancer. He also aims to develop new molecular diagnostic tests and less toxic, targeted therapies to treat relapsed or refractory neuroblastoma, including a major effort in immunotherapy discovery and development.
The cure rate for children with neuroblastoma is unacceptable, making it imperative that new therapies are developed. Dr. Bosse's laboratory is focused on discovering and developing new neuroblastoma cell surface immunotherapeutic targets. Along with his colleagues, Dr. Bosse's aim is to capitalize on the robust differential expression of these molecules with immune-based therapies and also define their mechanisms of overexpression and roles in tumorigenesis.
Dr. Broedur’s research interests focus on nanoparticle drug delivery and cancer predisposition. He is also interested in identifying novel cancer predisposition genes, and developing enhanced surveillance techniques to identify cancer early in predisposed individuals with the hope of improving outcome and reducing side effects.
Dr. Sgourakis’ research focuses on understanding the intricate molecular mechanisms that determine the vast repertoire of peptide antigens displayed by the proteins of the Major Histocompatibility Complex for immune surveillance by T cells and Natural Killer cells.
Dr. Huang works on methodology development to understand the dynamics of disease activities and inform health management using multivariate longitudinal health data. She also works on data integration in Clinical Research Networks.
Dr. Smith is a laboratory animal medicine veterinarian. As Technical Director of the CCMT Comparative Medicine Services Core, he helps guide promising therapeutics and devices from discovery and developmental studies through nonclinical studies.
In this Q&A, Drs. Teachey and Diorio discuss their partnership and research of a novel CAR T-cell therapy for one of the most common pediatric cancers.
